30,315 Shares in Bristol Myers Squibb Company $BMY Acquired by Global Retirement Partners LLC

Global Retirement Partners LLC bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 30,315 shares of the biopharmaceutical company’s stock, valued at approximately $1,403,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Eley Financial Management Inc raised its holdings in Bristol Myers Squibb by 2.7% during the second quarter. Eley Financial Management Inc now owns 36,200 shares of the biopharmaceutical company’s stock valued at $1,676,000 after buying an additional 948 shares in the last quarter. Prudential Financial Inc. increased its holdings in shares of Bristol Myers Squibb by 165.9% during the 2nd quarter. Prudential Financial Inc. now owns 3,741,736 shares of the biopharmaceutical company’s stock valued at $173,205,000 after acquiring an additional 2,334,421 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares in the last quarter. American Century Companies Inc. lifted its holdings in Bristol Myers Squibb by 4.3% in the 2nd quarter. American Century Companies Inc. now owns 2,354,441 shares of the biopharmaceutical company’s stock worth $108,987,000 after purchasing an additional 97,089 shares during the last quarter. Finally, Private Management Group Inc. bought a new stake in Bristol Myers Squibb during the second quarter worth approximately $951,000. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on BMY shares. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Citigroup decreased their price target on shares of Bristol Myers Squibb from $48.00 to $45.00 and set a “neutral” rating for the company in a report on Monday, November 17th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Four equities research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $54.42.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $49.33 on Thursday. The firm’s 50-day moving average is $45.43 and its 200-day moving average is $46.60. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company has a market cap of $100.43 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 2.23 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same quarter last year, the company earned $1.80 earnings per share. The firm’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.0%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 83.78%.

Insider Activity

In related news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.07% of the company’s stock.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.